I agree that this site is using cookies. You can find further informations here.
X
Bjørnhart, Birgitte
22  results:
Search for persons X
?
1

Clinical impact of venous thromboembolism in non-small cell..:

Bjørnhart, Birgitte ; Kristiansen, Charlotte ; Asmussen, Jon...
Thrombosis Research.  221 (2023)  - p. 164-172 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Clinical features affecting efficacy of immune checkpoint i..:

Mouritzen, Mette T. ; Junker, Karen F. ; Carus, Andreas...
Acta Oncologica.  61 (2022)  4 - p. 409-416 , 2022
Link: https://doi.org/10.1080/..
 
?
3

Effect and Tolerability of Immunotherapy in Patients with N..:

Bjørnhart, Birgitte ; Hansen, Karin Holmskov ; Asmussen, Jon Thor...
Cancers.  14 (2022)  7 - p. 1682 , 2022
Link: https://doi.org/10.3390/..
 
?
4

Incidence, risk factors and clinical outcome of venous thro..:

Bjørnhart, Birgitte ; Hansen, Karin Holmskov ; Jørgensen, Trine Lembrecht..
Thrombosis Update.  4 (2021)  - p. 100056 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Nationwide Survival Benefit after Implementation of First-L..:

Mouritzen, Mette T. ; Carus, Andreas ; Ladekarl, Morten...
Cancers.  13 (2021)  19 - p. 4846 , 2021
Link: https://doi.org/10.3390/..
 
?
6

Plasma TNF binding capacity in patients with juvenile idiop..:

Bjørnhart, Birgitte ; Svenningsen, Pernille ; Gudbrandsdottir, Sif...
International Immunopharmacology.  5 (2005)  1 - p. 73-77 , 2005
Link: https://doi.org/10.1016/..
 
?
7

Clinical features affecting efficacy of immune checkpoint i..:

Mouritzen, Mette T ; Junker, Karen F ; Carus, Andreas...
Mouritzen , M T , Junker , K F , Carus , A , Ladekarl , M , Meldgaard , P , Nielsen , A W M , Livbjerg , A , Larsen , J W , Skuladottir , H , Kristiansen , C , Wedervang , K , Schytte , T , Hansen , K H , Østby , A-C , Frank , M S , Lauritsen , J , Sørensen , J B , Langer , S W , Persson , G F , Andersen , J L , Homann , P H , Kristensen , E B , Drivsholm , L B , Bøgsted , M , Christensen , H S , Pøhl , M & Bjørnhart , B 2022 , ' Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC : a Danish nationwide real-world study ' , Acta Oncologica , vol. 61 , no. 4 , pp. 409-416 . https://doi.org/10.1080/0284186X.2021.2023213.  , 2022
Link: https://portal.findresea..
 
?
8

Clinical features affecting efficacy of immune checkpoint i..:

Mouritzen, Mette T ; Junker, Karen F ; Carus, Andreas...
https://pure.au.dk/portal/en/publications/e084f07b-840e-4ec0-b6aa-4514e6233d27.  , 2022
Link: https://pure.au.dk/porta..
 
?
9

Clinical features affecting efficacy of immune checkpoint i..:

Mouritzen, Mette T ; Junker, Karen F ; Carus, Andreas...
https://vbn.aau.dk/da/publications/686eb154-1718-4f76-8653-85dceaffd10e.  , 2022
Link: https://vbn.aau.dk/da/pu..
 
?
10

Effect and Tolerability of Immunotherapy in Patients with N..:

Bjørnhart, Birgitte ; Hansen, Karin Holmskov ; Asmussen, Jon Thor...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997168/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Effect and Tolerability of Immunotherapy in Patients with N..:

Bjørnhart, Birgitte ; Hansen, Karin Holmskov ; Asmussen, Jon Thor...
Bjørnhart , B , Hansen , K H , Asmussen , J T , Jørgensen , T L , Herrstedt , J & Schytte , T 2022 , ' Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis ' , Cancers , vol. 14 , no. 7 , 1682 . https://doi.org/10.3390/cancers14071682.  , 2022
Link: https://portal.findresea..
 
?
12

Nationwide survival benefit after implementation of first-l..:

Mouritzen, Mette T ; Carus, Andreas ; Ladekarl, Morten...
https://pure.au.dk/portal/en/publications/463a0d26-4996-4119-8c74-1e77d33c4377.  , 2021
Link: https://pure.au.dk/porta..
 
?
13

Nationwide survival benefit after implementation of first-l..:

Mouritzen, Mette T ; Carus, Andreas ; Ladekarl, Morten...
Mouritzen , M T , Carus , A , Ladekarl , M , Meldgaard , P , Nielsen , A W M , Livbjerg , A , Larsen , J W , Skuladottir , H , Kristiansen , C , Wedervang , K , Schytte , T , Hansen , K H , Østby , A C , Frank , M S , Lauritsen , J , Sørensen , J B , Langer , S W , Persson , G F , Andersen , J L , Frary , J M C , Drivsholm , L B , Vesteghem , C , Christensen , H S , Bjørnhart , B & Pøhl , M 2021 , ' Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy ' , Cancers , vol. 13 , no. 19 , 4846 . https://doi.org/10.3390/cancers13194846.  , 2021
Link: https://portal.findresea..
 
?
14

Incidence, risk factors and clinical outcome of venous thro..:

Bjørnhart, Birgitte ; Holmskov Hansen, Karin ; Jørgensen, Trine Lembrecht..
Bjørnhart , B , Holmskov Hansen , K , Jørgensen , T L , Herrstedt , J & Schytte , T 2021 , ' Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition ' , Thrombosis Update , vol. 4 , 100056 . https://doi.org/10.1016/j.tru.2021.100056.  , 2021
Link: https://portal.findresea..
 
?
15

Nationwide Survival Benefit after Implementation of First-L..:

Mouritzen, Mette T ; Carus, Andreas ; Ladekarl, Morten...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507718/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
1-15